July 28, 2021
ARIEL4 Trial Confirms PFS Benefit of Rucaparib in BRCA+ Relapsed Ovarian Cancer BookmarkGeorge Lundberg, MD
As reported by Cancer Network, new results from a phase 3 clinical trial testing the drug rucaparib (Rubraca), which has already been approved by the U.S. Food and Drug Administration, show that it prolongs progression-free survival in some patients with advanced ovarian cancer.
November 24, 2020
Two New Treatments Approved For Advanced Prostate Cancer BookmarkGeorge Lundberg, MD
A story published by the Prostate Cancer Foundation outlines two new treatment options approved by the U.S. Food and Drug Administration (FDA) this year. The two medications, rucaparib and olaparib, each target specific mutations that may be found in a patient’s tumor, and each was approved for a specific type of prostate cancer.